Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1987 1
1988 1
1990 1
2004 1
2008 1
2009 2
2010 1
2011 1
2012 2
2013 3
2016 1
2017 1
2018 1
2019 1
2020 4
2021 2
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

27 results

Results by year

Filters applied: . Clear all
Page 1
Cognitive Dysfunctions and Assessments in Multiple Sclerosis.
Oreja-Guevara C, Ayuso Blanco T, Brieva Ruiz L, Hernández Pérez MÁ, Meca-Lallana V, Ramió-Torrentà L. Oreja-Guevara C, et al. Among authors: hernandez perez ma. Front Neurol. 2019 Jun 4;10:581. doi: 10.3389/fneur.2019.00581. eCollection 2019. Front Neurol. 2019. PMID: 31214113 Free PMC article. Review.
Expert-Agreed Practical Recommendations on the Use of Cladribine.
Meca-Lallana V, García Domínguez JM, López Ruiz R, Martín-Martínez J, Arés Luque A, Hernández Pérez MA, Prieto González JM, Landete Pascual L, Sastre-Garriga J. Meca-Lallana V, et al. Among authors: hernandez perez ma. Neurol Ther. 2022 Dec;11(4):1475-1488. doi: 10.1007/s40120-022-00394-0. Epub 2022 Sep 6. Neurol Ther. 2022. PMID: 36068429 Free PMC article.
Diroximel fumarate in patients with relapsing-remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study.
Singer BA, Arnold DL, Drulovic J, Freedman MS, Gold R, Gudesblatt M, Jasinska E, LaGanke CC, Naismith RT, Negroski D, Oh J, Hernandez Perez MA, Selmaj K, Then Bergh F, Wundes A, Ziemssen T, Castro-Borrero W, Chen H, Levin S, Scaramozza M, Shankar SL, Wang T, Wray S. Singer BA, et al. Among authors: hernandez perez ma. Mult Scler. 2023 Dec;29(14):1795-1807. doi: 10.1177/13524585231205708. Epub 2023 Oct 31. Mult Scler. 2023. PMID: 37905526 Free PMC article.
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023.
Meca-Lallana JE, Martínez Yélamos S, Eichau S, Llaneza MÁ, Martín Martínez J, Peña Martínez J, Meca Lallana V, Alonso Torres AM, Moral Torres E, Río J, Calles C, Ares Luque A, Ramió-Torrentà L, Marzo Sola ME, Prieto JM, Martínez Ginés ML, Arroyo R, Otano Martínez MÁ, Brieva Ruiz L, Gómez Gutiérrez M, Rodríguez-Antigüedad Zarranz A, Sánchez-Seco VG, Costa-Frossard L, Hernández Pérez MÁ, Landete Pascual L, González Platas M, Oreja-Guevara C. Meca-Lallana JE, et al. Among authors: hernandez perez ma. Neurologia (Engl Ed). 2024 Mar;39(2):196-208. doi: 10.1016/j.nrleng.2024.01.003. Epub 2024 Jan 16. Neurologia (Engl Ed). 2024. PMID: 38237804 Free article.
Review of the novelties presented at the 27th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) (I).
Fernández Ó, Álvarez-Cermeño JC, Arroyo-González R, Brieva L, Calles-Hernández MC, Casanova-Estruch B, Comabella M, de las Heras V, García-Merino JA, Hernández-Pérez MA, Izquierdo G, Meca-Lallana JE, Muñoz-García D, Olascoaga J, Oreja-Guevara C, Prieto JM, Ramió-Torrentà L, Rodríguez-Antigüedad A, Romero-Pinel L, Sanchez F, Téllez N, Tintoré M, Montalban X; Post-ECTRIMS group. Fernández Ó, et al. Among authors: hernandez perez ma. Rev Neurol. 2012 Jun 1;54(11):677-91. Rev Neurol. 2012. PMID: 22627749 Free article. Review. English, Spanish.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Platas M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X. Meca-Lallana JE, et al. Among authors: hernandez perez ma. Neurologia (Engl Ed). 2020 Jan 25;37(8):615-630. doi: 10.1016/j.nrl.2019.11.003. Print 2022 Oct. Neurologia (Engl Ed). 2020. PMID: 31987648 Free article. English, Spanish.
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain.
Meca-Lallana JE, Fernández-Prada M, García Vázquez E, Moreno Guillén S, Otero Romero S, Rus Hidalgo M, Villar Guimerans LM, Eichau Madueño S, Fernández Fernández Ó, Izquierdo Ayuso G, Álvarez Cermeño JC, Arnal García C, Arroyo González R, Brieva Ruiz L, Calles Hernández C, García Merino A, González Plata M, Hernández Pérez MÁ, Moral Torres E, Olascoaga Urtaza J, Oliva-Nacarino P, Oreja-Guevara C, Ortiz Castillo R, Oterino A, Prieto González JM, Ramió-Torrentá L, Rodríguez-Antigüedad A, Saiz A, Tintoré M, Montalbán Gairin X. Meca-Lallana JE, et al. Among authors: hernandez perez ma. Neurologia (Engl Ed). 2022 Oct;37(8):615-630. doi: 10.1016/j.nrleng.2019.11.001. Epub 2020 Mar 12. Neurologia (Engl Ed). 2022. PMID: 36195374 Free article.
Successful desensitization to natalizumab using a 1-solution protocol.
Pérez-Rodríguez E, Hernández-Pérez MÁ, Martínez-Tadeo JA. Pérez-Rodríguez E, et al. Among authors: hernandez perez ma. Ann Allergy Asthma Immunol. 2017 Jan;118(1):113-114. doi: 10.1016/j.anai.2016.10.009. Epub 2016 Nov 15. Ann Allergy Asthma Immunol. 2017. PMID: 27864092 No abstract available.
27 results